SOPHiA GENETICS SA (SOPH) is a global health tech company that is leading the charge in data-driven medicine. The company uses artificial intelligence (AI) to analyze genetic data and improve patient outcomes across a broad spectrum of diseases. SOPHiA GENETICS, which combines deep learning algorithms and genomic big data, was established with the mission to democratize data-driven medicine so that everyone can benefit.
SOPHiA GENETICS was founded in Switzerland in 2011 by Jurgi Camblong, Lars Steinmetz, and Pierre Hutter, and quickly established itself as a pioneer in data-driven medicine. The company’s AI, known as SOPHiA, is an advanced system that learns from every genomic sequencing it processes, making it smarter and more efficient with each use. The firm provides technology to over 1,000 hospitals in more than 80 countries, decoding human genome and helping clinicians better diagnose and treat patients.
The company focuses on oncology and hereditary disorders, with its innovative technology analyzing DNA sequencing data to detect molecular alterations or genetic mutations that may cause diseases. By predicting the impact of these genetic variations and detecting biomarkers for disease, SOPHiA GENETICS can support clinical researchers and healthcare professionals in their patient care decisions.
SOPHiA's unique AI platform allows for high-precision, scalable, and robust genomic analysis, giving its partners an unparalleled edge in clinical diagnostics and therapeutics. The company's AI algorithms can accurately detect and quantify complex genetic variants, such as point mutations, copy number alterations, and structural variants, making it a trusted resource for genome analysis and interpretation.
The company aims to empower medical professionals and help patients around the world through the implementation of its complex AI algorithms and extensive genetic databases. As the leading force in data-driven medicine, SOPHiA GENETICS SA is expanding the boundaries of the medical field and contributing significantly to personalised medicine, leading the fight against complex genetic diseases and cancer.
SOPHiA GENETICS is publicly traded with the ticker symbol SOPH and has continuously shown growth, a testament to its innovative technology and vision. The company also works in close collaboration with biopharmaceutical companies and academic institutions worldwide, further contributing to its reputation as a trusted, leading player in the genomic healthcare sector. With a strong commitment to transforming healthcare through technology, SOPHiA GENETICS SA continues to prove its worth in the ever-evolving health tech space.